Division of Institut Merieux
Latest From Transgene SA
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
In an exclusive interview, Japanese tech giant NEC tells Scrip it is aiming for much more than the provision of IT tools in its AI-assisted Drug Discovery Initiative, hoping also to progress assets deriving from cutting-edge technology research.
- Therapeutic Areas
- Hepatic (Liver)
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Institut Merieux
- Senior Management
Philippe Archinard, PhD, Chmn. & CEO
Jean-Philippe Del, VP, Fin.
Thibaut du Fayet, PhD, VP, Alliance Mngmt., Project Mngmt. & Mktg.
Maud Brandely, MD, PhD, CMO
- Contact Info
Phone: (33) 3 88 27 91 00
400 Boulevard Gonthier d'Anderach
Illkirch Graffenstaden, F-67405
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.